Samsung Biologics secured two manufacturing contracts worth 930.4 billion won ($668.39 million) with a European pharmaceutical company, pushing its annual orders past 5 trillion won for the first time.
The South Korean contract manufacturer signed deals extending through 2031, with the larger agreement valued at 752.4 billion won. These contracts mark the latest in a series of major wins for Samsung Biologics, which has seen its order book expand 1.5 times compared to last year.
The company landed three deals worth over 1 trillion won each in 2023, including a 1.46 trillion won contract with a U.S. drugmaker in July and a 1.7 trillion won agreement with an Asian pharmaceutical firm in October.
To meet rising demand, Samsung Biologics is constructing its fifth plant, an 18,000-liter facility set to begin operations in April 2025. This expansion will boost total production capacity to 784,000 liters.
The company maintains a 99% batch success rate and has secured 339 manufacturing approvals from global regulators. Its client roster includes 17 of the world’s top 20 pharmaceutical companies, with cumulative orders exceeding $16.1 billion since its founding.
Looking to expand further, Samsung Biologics plans to open a sales office in Tokyo while strengthening its presence at major industry events across the U.S., Europe, and Asia.
